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The conjugate of acid labile cis-aconityl-daunomycin (cAD) with branched chain polypeptide, poly[Lys(Glui-DL-Alam)] (EAK) was very
effective against L1210 leukemia in mice. However, Dau attached to a polycationic polypeptide, poly[Lys(Seri-DL-Alam)] (SAK) exhibited no in
vivo antitumor effect. In order to understand this difference we have performed comparative in vitro studies to dissect properties related to
interaction with the whole body (e.g., biodistribution) from those present at cellular or even molecular level. We report here (a) the kinetics of acid-
induced Dau liberation, (b) interaction with DPPC phospholipid bilayer, (c) in vitro cytotoxic effect on different tumor cells, and (d) intracellular
distribution in HL-60 cells of polycationic (cAD-SAK) and amphoteic (cAD-EAK) conjugates. Fluorescence properties of the two conjugates are
also reported. Our findings demonstrate that the kinetics of the drug release, intracellular distribution and in vitro cytotoxic effect are rather similar,
while the effect on DPPC phospholipid bilayer and fluorescence properties of the two conjugates are not the same. We also found that the in vitro
cytotoxicity is cell line dependent. These observations suggest that the structure of the polypeptide carrier could have marked influence on drug
uptake related events.
© 2005 Elsevier B.V. All rights reserved.Keywords: Polypeptide carrier; Daunomycin; pH-dependent drug liberation; Altered conjugate cytotoxicity; Uptake of daunomycin conjugate1. Introduction
Synthetic linear and branched chain polymers are utilized as
macromolecular carriers for “passive” delivery of bioactive
molecules. These conjugates could exhibit improved solubility,
beneficial pharmacological properties (extended blood survival,
specific tissue accumulation), diminished cytotoxicity and
increased therapeutic efficacy as compared to the free drugs,
radionuclides [1–3]. Among synthetic linear poly-α-amino
acids, polyanionic poly(L-glutamic acid), poly(L-aspartic acid)
and polycationic poly(L-lysine), poly(L-Orn) have been used⁎ Corresponding author. Research Group of Peptide Chemistry, Hungarian
Academy of Sciences, Pázmány P. sétány 1A, Budapest H-1117, Hungary. Tel.:
+36 1 372 2828; fax: +36 1 372 2620.
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0005-2736/$ - see front matter © 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2005.12.008for delivery of antitumor agents, enzymes or albumin. Poly
(L-lysine) or poly(D-lysine) as lysosomotropic agent was coupled
with various antitumor drugs like, methotrexate, (MTX), adria-
mycin, daunomycin (Dau), mitomycin C or oligonucleotide
[2,4,5]. However, very few systematic studies were reported
on structural and functional factors required for optimal
polypeptide carrier. Therefore we have prepared and investi-
gated structural and biological characteristics of new groups
of branched chain polypeptides with the general formula of
poly[Lys(Xi-DL-Alam)] (XAK), poly[Lys(Xi-DL-Serm), (XSK),
poly[Lys(Xi)] (XiK) or poly[Lys(DL-Alam-Xi)] (AXK) where
i=1, m=3, and X represent an additional optically active
amino acid residue [6–8]. We have demonstrated that the side
chain composition and amino acid sequence of the branches
have marked influence on blood clearance, biodistribution [8,9],
immunogenicity [6,8] and also on the interaction with
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thesized various conjugates in which antitumor agents (dauno-
mycin [11,12], MTX [13,14], GnRH antagonist [15], amiloride
[16], radionuclides [17,18] or epitope peptides [19] have been
covalently attached to selected structurally related branched
polymeric polypeptides. Pronounced antitumor activity of Ac-
[D-Trp1–3, D-Cpa2, D-Lys6, D-Ala10]-GnRH-poly[Lys(Ac-
Glui-DL-Alam)] (Ac-EAK) conjugate has been clearly docu-
mented [15]. We have also demonstrated that the effect of
peptide conjugates on phospholipid membranes (DPPC, DDPC/
PG) is mainly determined by the charge and charge density
properties of the carrier polypeptide [20,21]. Carrier-dependent
anti-Leishmania donovani effect of MTX-polypeptide conju-
gates was observed in vitro and in vivo [14]. The coupling of
acid labile cis-aconityl-daunomycin (cAD) to poly[Lys(Glui-
DL-Alam)] (EAK) resulted in compensation of the immuno-
suppressive effect of the daunomycin (Dau) and this polymeric
conjugate in vivo was very effective against L1210 leukemia
producing 66–100% long-term survivors (N60 days) in mice
[22]. However, cAD attached to a polycationic polypeptide,
poly[Lys(Seri-DL-Alam)] (SAK) exhibited no in vivo antitumor
effect under similar conditions [12].
In order to understand the differences observed in antitumor
activity in vivo, we have performed comparative studies in
vitro. Thus, properties related to interaction between the whole
body and conjugates (e.g., blood clearance, tissue distribution)
could be dissected from those present at cellular or even
molecular level. It should be noted that branched polypeptides
SAK and EAK are differ only in a single amino acid residue
situated at the end of the branches (Fig. 1). However, the
presence of different amino acids (Ser in SAK and Glu in EAK)
at the side chain terminal position results in altered charge and
conformational properties: polypeptide EAK is amphoteric andFig. 1. Schematic structure of daunomycin-branched chaiadopt essentially disordered conformation under nearly phys-
iological conditions (0.2 M NaCl, pH 7.4) [23]. In contrast
polypeptide SAK exhibits polycationic characteristics and
proved to be markedly ordered in 0.2 M NaCl at pH 7.2, [7].
Under these conditions the calculated α-helix content was
53.1% for SAK, and 6.3% for EAK. Even more pronounced
difference was observed in the presence of DPPC (e.g., 71.9%
α-helix content for SAK and 7.8% for EAK) or DPPC/PG
mixtures [24].
Considering the potential differences of conjugates in acid-
induced release of Dau, in their interaction with phospholipid
bilayer and in biological activity, the aim of present study was to
compare the (a) liberation kinetics of the drug, (b) effect of
conjugates on DPPC phospholipid bilayer, (c) in vitro cytotoxic
effect of conjugates on four different tumor cell lines, and (d)
cellular distribution after uptake by HL-60 cells using confocal
laser microscopy. To exclude artefacts fluorescence properties of
daunomycin as well as of the two conjugates (cAD-EAK and
cAD-SAK) are also reported. Our findings demonstrate that the
kinetics of the drug release, the in vitro cytotoxic effect and
intracellular distribution are rather similar, while the effect on
DPPC phospholipid bilayer and fluorescence properties of the
two conjugates are not the same. We found also that the in vitro
cytotoxicity of conjugates is cell line dependent. These
observations suggest that the structure of the polypeptide carrier
could have marked influence on drug uptake related events.2. Materials and methods
2.1. Materials
Daunomycin hydrochloride was a gift from the Institute of Drug Research
Ltd. Budapest, Hungary; cis-aconitic-anhydride,N-ethyl-N′-[3-(dimethylamino)n polypeptide conjugates, cAD-EAK and cAD-SAK.
Fig. 2. Analytical RP-HPLC profile of the mixture of daunomycin, cis-aconityl-
daunomycin and cAD-EAKconjugate. The isocratic elutionwas developed using
eluent: (NH4)2CO3(3w/w%):MeOH=50:50 v/v. Column: C18Delta Pak column
(3.9 mm×300 mm, 15 μm silica, 300 Å pore size). Flow rate was 1 ml/min at
room temperature. 20 μl of the samples were injected, and peaks were detected at
λ=490 nm.
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diphenyltetrazolium bromide (MTT), DME:F12 medium powder, RPMI-1640
medium powder, glutamine, gentamycin, DPPC (dipalmitoyl phosphatidyl
choline) were from Sigma-Aldrich (Budapest, Hungary). Fetal bovine serum
(FBS) was obtained from Gibco Brl. Solvents (dioxane, methanol, acetonitrile,
dimethyl sulfoxide (DMSO)), trifluoroacetic acid (TFA) and other chemicals for
buffers and eluents were obtained from Reanal, Budapest, Hungary. Solvents
(chloroform, tetrahydrofuran) used were Merck analytical grade products.
Fluorescent probes DHP (1, 6-diphenyl-1, 3, 5 hexatriene) and TMA-DPH [1-
(trimethylammoniumphenyl)-phenyl-1, 3, 5 hexatriene p-toluene-sulfonate were
from Molecular Probes (Eugene, Oregon, USA).
cis-Aconityl daunomycin (cAD), poly[Lys-(Glu0.9-DL-Ala3.0)], (EAK),
poly[Lys-(Ser1.0-DL-Ala3.5)], (SAK), poly[Lys-(cADi-Glui-DL-Alam)], (cAD-
EAK) and poly[Lys-(cADi-Seri-DL-Alam)], (cAD-SAK) were synthesized in
our laboratory [11,12] as described in detail for cAD-EAK previously [11].
Briefly, the coupling of cAD to branched polypeptide with M
P
w ¼ 36500
ðDPPn ¼ 80Þ for EAK and withMPw ¼ 34000 ðDPPn ¼ 80Þ for SAK was achieved
by a carbodiimide method. The carboxyl groups of cAD were activated by
water-soluble carbodiimide using 1.5 times molar excess of EDAC. The cAD-
conjugate preparations were purified by gel-filtration and characterized by
reversed-phase HPLC, cAD content, average degree of substitution ðDSPÞ and
ðMPwÞ determination. 1 mg of cAD-EAK conjugate sample ðDSP ¼ 5:4%Þ used
in this study contained 0.08 μmol (0.042 mg) daunomycin. 1 mg of cAD-SAK
conjugate sample ðDSP ¼ 3:3%Þ used in this study contained 0.05 μmol (0.025
mg) daunomycin.
2.2. Release of the drug from the cAD-branched chain polypeptide
conjugates
Liberation of daunomycin from its cis-aconityl-daunomycin conjugates
was studied by analytical RP-HPLC on a Delta Pak C18 column (3.9×300
mm, packed with 15 μm silica, 300 Å pore size). The isocratic elution was
developed using (NH4)2CO3(3 w/w%):MeOH=50:50, v/v as mobile phase
using a flow rate of 1 ml/min at room temperature. Peaks were detected at
λ=490 nm. The samples were dissolved in 0.1 M citrate-phosphate buffer at
various pH (3, 4, 5, 6 or 7.4). The concentration of samples was 0.5 mg/ml for
Dau content. The solutions were kept at 25 °C or 37 °C for various time
periods up to 72 h. The amount of free daunomycin released from cAD-
conjugates was determined by using calibration curves. Calibration curves for
daunomycin, cis-aconityl-daunomycin were established as follows. The
compounds were dissolved in 0.1 M citrate-phosphate buffer (pH 7.4) at
concentration of 0.5 mg/ml for daunomycin content and 20 μl of solutions
were injected into RP-HPLC column. Calibration curves derived from the area
under the curve (AUC) and drug concentration was calculated from 2 to 5
parallel measurements.
2.3. Preparation of labeled DPPC liposomes
Small unilamellar liposomes of DPPC were prepared by sonication as
described before [25]. Briefly, stock solution of DPPC in chloroformwas dried to
a film using a rotary evaporator. Lipids were hydrated with sodium-acetate buffer
(pH 7.4). Sonication was performed using anMSEUltrasonic Desintegrator. The
power output was approx. 150W. Clear solutions were obtained after 15–20 min
sonication. The size distribution of liposome preparation was checked by light
scattering measurement. The final phospholipid concentration in the stock
solution was 1.5 mM. Liposomes were incubated with either DHP or TMA-DPH
(at c=10−5 M) [26] at 55 °C (higher than the phase transition temperature of
DPPC) at the saturation concentration of vesicles.
2.4. Analysis of interaction between DPPC liposome and
cAD-conjugates
Daunomycin or cAD-conjugates were added to the DHP/TMA-DPH labeled
liposomes to result in a 2.4×10− 5 M final daunomycin concentration and 300:
1= lipid : daunomycin ratio and fluorescence measurements were performed
after 1 h incubation. Steady-State fluorescence measurements were carried out
using an Aminco-Bowman spectrofluorimeter provided with a thermostated fourpositions cuvette holder. The temperature was controlled using a circulatory bath
(Techne), and samples were continuously stirred. Fluorescence anisotropy of
DHP and TMA-DPH in the temperature range 25–50 °C at 2 degrees intervals,
was measured at excitation wavelength of λ=355 nm and monitoring
wavelength at λ=430 nm for TMA-DPH and λ=426 nm for DHP.
Anisotropy-temperature curves were recorded. From the first derivative of
each curve the respective transition from gel to liquid crystalline state (Tc value)
was determined.
The fluorescence anisotropy was defined as:
A ¼ IVV  GIVH
IVV þ 2GIVH
where IVV and IVH are observed intensities measured with emission polarizers
parallel and perpendicular to the vertically polarized exciting beam, res-
pectively. G is a wavelength dependent factor used to correct for the inability
of the instrument to transmit differently polarized light equally. Values were
corrected for background light-scattering and samples containing unlabeled
suspension.
2.5. Fluorescence spectroscopy
Daunomycin and its polypeptide conjugates (cAD-EAK or cAD-SAK) were
dissolved in 0.1 M citrate-phosphate buffer at various pH (3, 4, 5, 6 and 7.4)
directly before spectral recordings. The daunomycin concentration of samples
was determined by absorption spectroscopy using Cary 4 E spectrophotometer
and adjusted to 3.276×10−5 M.
Corrected steady-state emission and excitation spectra of daunomycin and
its polypeptide conjugates were obtained using a FS900CD spectrofluorimeter
(Edinburgh Analytical Instruments, UK) with a Xe lamp excitation and a
Hammamatsu photomultiplier (R955) detection. Emitted fluorescence intensity
was measured at an angle 90° relative to the exciting light. Resolution of
monochromators was 0.5 nm. The excitation wavelength was λ=488 nm, and
the emission spectra were recorded between λ=475–800 nm.
2.6. Cell culture
The c26 mouse colon carcinoma and MDA-MB 435 P human breast
carcinoma adherent cell lines were cultured at 37 °C and 5% CO2 in DME:
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mouse and HL-60 human lymphoid suspension cell lines were cultured at 37 °C
and 5% CO2 in RPMI-1640 medium containing 10% FBS, 2 mM glutamine and
160 μg/ml gentamycin.
2.7. In vitro cytotoxicity of cAD-conjugates
The cells were placed in 96-well plate with each well containing 5×103
cells. After incubation at 37 °C for 24 h, the cultured cells were treated with
daunomycin, or with cAD-EAK, cAD-SAK conjugates dissolved in serum-free
DME-F12 or RPMI-1640 medium. For the treatment, compounds were used in
the 10−9–10−3 M concentration range for daunomycin content. In control
experiments, cells were treated with serum-free medium only at 37 °C. After
incubation for 3 h, cells were washed with serum-free medium three times and
serum-containing medium was added to the cells. After 4 days at 37 °C, the 3-
(4,5-dimehyltiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)-assay was
carried out. The yellow solution of MTT at concentration of 2 mg/ml was
added to each well. The purple crystal obtained was solved in 100 μl DMSO and
the optical density (OD) of the samples was measured at λ=540 nm using
ELISA Reader (Labsystems, Finland). We have calculated the % of cytotoxicity
using the following equation:
Cytotoxicity %= (1−ODtreated /ODcontrol) × 100, where ODtreated and
ODcontrol correspond to the optical density of the samples from treated cells
and the control cells at λ=540 nm, respectively.
2.8. Curve fitting
Results obtained from the daunomycin release studies and from in vitro
cytotoxicity measurements were analysed by Origin 5.0 software using
exponential and sigmoid curve fitting, respectively.Fig. 3. pH and temperature dependence of the drug release from cAD-EAK (A and
respectively) conjugates detected by analytical RP-HPLC. Elution was carried out a
(c=0.5 mg/ml for daunomycin content) at pH 7.4 (▾), pH 6 (⋄), pH 5 (▴), pH 4 (2.9. Uptake of the conjugates by HL-60 human lymphoid leukemia
cells
The cells were placed in 24-well plate with each well containing 5×105 cells/
1 ml medium. Cells were treated with daunomycin, cAD-EAK, or cAD-SAK
conjugate at the 2 μM concentration for Dau content. The control cells were
treated with EAK or SAK polypeptide, or incubated with medium only.
Compounds were dissolved in serum-free DME-F12 or RPMI-1640medium and
incubationwas carried out for 15min, 1, 3, 8 or 24 h. Then cells werewashedwith
PBS (0.1 M; pH 7.4) twice, stored at 4 °C for overnight. The living cells were
mounted onto microscopic slides and analysed using confocal scanning laser
microscope with λex=480 nm using MRC 1024 (Bio-Rad, California, USA).3. Results
In cAD-branched polypeptide conjugates one carboxyl
group of the cAD was linked to the α-amino group of the
side chain terminal Glu (EAK) or Ser (SAK) amino acid to
provide covalent α-amide bonding between branched polypep-
tide SAK or EAK and cAD (Fig. 1).
3.1. Release of the drug from the cis-aconityl-daunomycin
(cAD)-branched chain polypeptide conjugates (cAD-EAK and
cAD-SAK)
In order to mimic conditions of the endocytotic uptake pH
dependence of the liberation of the drug from daunomycin-C, 25 °C and 37 °C, respectively) and cAD-SAK (B and D, 25 °C and 37 °C,
s described in Fig. 2. Samples were dissolved in 0.1 M citrate-phosphate buffer
○) and pH 3 (n).
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amphoteric (cAD-EAK) polypeptide was studied as function
of pH (3, 4, 5, 6, 7), of time (up to 72 h) and of temperature
(25 °C and 37 °C). For these measurements, a reversed-phase
HPLC based methodology was developed and used for the
determination of the free drug released (Fig. 2). Fig. 3 shows
the drug release from the cAD-EAK (Fig. 3A, C) and cAD-
SAK (Fig. 3B, D) conjugates. We found that not only
daunomycin but also cis-aconityl-daunomycin are released
from both conjugates under conditions studied (data not
shown). At nearly physiological pH, mimicking extracellular
and intracellular circumstances, only 1–2% of the drug
(daunomycin plus cAD) was released even after 72 h from
cAD-EAK conjugate at 25 °C and about 6–8% at 37 °C (Fig.
3C). Under acidic circumstances, the drug release significantly
increased to 8% at pH 6.0; 23% at pH 5.0; 34% at pH 4.0 and
about 50% at pH 3.0 after 72 h incubation period at 25 °C.
Interestingly, about 100% of the drug was released after 72-
h incubation at pH 3.0 at 37 °C. At physiological pH again
only 3–4% at 25 °C and 10–12% at 37 °C (Fig. 3B) of the
drug was released from the polycationic cAD-SAK conjugate.
Lowering the pH resulted in increased drug liberation to yield
8% at pH 6.0, 55% at pH 3.0 after 72 h at 25 °C. However,Fig. 4. Interaction between cAD-EAK (A and C) or cAD-SAK (B and D) and lipos
conjugate •). The study was performed by fluorescence anisotropy method as descralmost the total amount of daunomycin was liberated at pH
3.0 after 72 h incubation at 37 °C (Fig. 3D).
3.2. Interaction between DPPC liposomes and cAD-conjugates
The interaction between cAD-conjugates and phospholipid
membranes was investigated using a very simple phospholipid
bilayer, DPPC. A fluorescent probe with positive electrical
charge TMA-DPH as well as a hydrophobic one, 1,6-diphenyl-
1,3,5-hexatriene (DPH), were used to analyse the effect of cAD-
polypeptide conjugates and daunomycin (data not shown) on
the outer surface and on hydrophobic core of bilayers [26]. For
these studies small unilamellar vesicles (SUVs) were used, so
that light scattering was not important. Changes in fluorescence
intensity and/or polarization of probes in bilayers were
determined as a function of temperature. Transition from gel
to liquid crystalline state (Tc ∼ 40–41.5 °C for DPPC) was
characterized by the analysis of Tc values in the presence or
absence of conjugates. The optimal probe/phospholipid molar
ratios were determined by incubation of plain liposomes with
increasing volumes of concentrated solutions of each label
followed by fluorescence intensity measurements. Up to a
certain label/lipid relationship, there was no increase in theome of DPPC 100% composition using DPH or TMA-DPH marker (buffer □,
ibed in Materials and methods.
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already saturated and stable. Under conditions applied (neutral
pH, low conjugate concentration, probe/phospholipid ratio),
liposomes composed of DPPC could be considered neutral.
Our experiments suggest that cAD-EAK had significant
effect on the anisotropy of the TMA-DPH and also of DPH in
membranes with 100% DPPC (ΔTc=4 °C and ΔTc=3 °C)
(Figs. 4A and C). cAD-SAK exhibited essentially no interaction
under identical conditions (Figs. 4B and D). The data show that
cAD-EAK conjugate has pronounced destabilising effect not
only on the surface (ΔTc=4 °C), but also on the inner part of the
bilayer (ΔTc=3 °C) of the DPPC liposomes. In contrast, the
cAD-SAK conjugate caused only negligible effect (ΔTc=0–0,5
°C) on the phospholipid bilayers. We also observed that Dau
markedly interacted with the surface and also with inner part of
the DPPC phospholipid bilayer (data not shown).
3.3. In vitro antitumor effect of the conjugates in mouse and
human tumor cells
The antitumor activity of daunomycin-polypeptide conju-
gates (cAD-EAK, cAD-SAK) was studied and compared at
10−9–10−3 M concentration range (for daunomycin content) on
the following four tumor cell lines: L1210 mouse lymphoid
leukemia, c26 murine colon carcinoma, MDA-MB 435P humanFig. 5. The in vitro antitumor effect of cAD-EAK (▴), cAD-SAK (○) conjugates and
lymphoid leukemia cells (B), c26 murine colon carcinoma cells (C) and on MDA-MB
range of 10−9–10−3 M for daunomycin content and cytotoxicity was determined bybreast carcinoma and HL-60 human lymphoid leukemia cell line
using MTT-assay. The level of the cytotoxicity (%) caused by
conjugate treatment was studied as a function of concentration.
Based on these curves the IC50 values were determined. Results
summarizing inhibitory effect of conjugates are presented in
Fig. 5. The lowest IC50 values for the both conjugates were
measured in the case of HL-60 human leukemia cells (Fig. 5A),
indicating the most pronounced antitumor effect was observed
against these cells. The IC50 values for cAD-EAK (5.0 μM) and
for cAD-SAK (3.5 μM) conjugates obtained on HL-60 cells are
very similar. Higher IC50 values were calculated from curves
obtained with L1210 murine leukemia cells treated with these
conjugates (Fig. 5B). The IC50 value for cAD-SAK conjugate
was 30.8 μM and for cAD-EAK it was 51.3 μM. Fig. 5C shows
the effect of cAD-conjugates on c26 murine colon carcinoma
cells. The IC50 value of cAD-SAK conjugate (IC50=117.4 μM)
was much lower than that of the cAD-EAK conjugate
(IC50=629.9 μM), indicating that the cAD-SAK conjugate
has more potent inhibitory effect on c26 cell proliferation than
that of cAD-EAK conjugate. Almost identical IC50 values were
obtained from experiments with MDA-MB 435 P human breast
carcinoma cells (IC50=195.2 μM) for both conjugates (Fig.
5D). In our experiments, EAK or SAK carrier molecules had no
effect against all cell lines studied at the concentration range
examined (data not shown).daunomycin (n) on HL-60 human lymphoid leukemia cells (A), L1210 murine
435 P human breast carcinoma cells (D). The cells were treated with samples at a
MTT-assay as described in the Materials and methods.
Fig. 6. Intracellular distribution of daunomycin (A), cAD-EAK (B) and cAD-SAK (C) conjugates by living HL-60 human lymphoid leukemia cells. The cells were
incubated with daunomycin or cAD-polypeptide conjugates at concentration of 2 μM for daunomycin for 3 h. Cells were analysed by a confocal scanning laser
microscope at λex=480 nm using MRC 1024 (Bio-Rad).
Fig. 7. The effect of pH on the emission spectrum of daunomycin, cAD-EAK
and cAD-SAK conjugates. The daunomycin content of the sample was
3.276×10−5 M. pH 7.4 , pH 5.0 ––––––, pH 4.0 – – –, pH 3.0.
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leukemia cells
Considering that conjugates exhibited the most pronounced
antitumor effect against HL-60 cells cytotoxicity, we have
selected this cell line for uptake experiments. In order to
determine the localization of daunomycin, cAD-EAK and cAD-
SAK conjugates within HL-60 cells, confocal laser scanning
microscopy study was performed. The cells were treated with
daunomycin, cAD-EAK or cAD-SAK conjugates and also with
EAK or SAK polypeptide for 15 min, 1, 3, 8 or 24 h. Fig. 6
shows that daunomycin, cAD-EAK or cAD-SAK conjugates
accumulated in cells after 3 h incubation. After treatment with
daunomycin, we found that the nucleus had red fluorescence,
indicating that daunomycin could be mainly detected in the
nucleus (Fig. 6A). Opposite to the hypothesis for conjugates of
the literature, in the case of cAD-EAK or cAD-SAK conjugates
treatments we observed no red fluorescence in the nucleus,
while the cytoplasm exhibited red fluorescence, meaning that
the conjugates are present in the cytoplasm (Figs. 6B and C)
even after 8 or 24 h incubation (data not shown). It should be
noted that there are differences between the two confocal
microscopy images. In the case of cAD-EAK conjugate the
laser amplifier was in 100%, while in the case of cAD-SAK
conjugate this laser amplifier was only 30%. The untreated cells
or the cells treated with EAK or SAK polypeptide (data not
shown) alone had no autofluorescence behavior. To exclude
artefact deriving from the altered fluorescence properties of
conjugates fluorescence properties of the conjugates and Dau,
as control were investigated.
3.5. Fluorescence emission spectra of the daunomycin and its
peptide conjugates
For the better understanding of the results of confocal laser
scanning microscopy we compared the spectral characteristics
of the free Dau and that of cAD-EAK, cAD-SAK conjugates.
Fig. 7 shows the fluorescence emission spectra (λex=488 nm)
of solutions containing equimolar concentration of daunomy-cin. The absorbance of the solutions at the absorption maximum
of daunomycin was similar in the range of experimental error.
As one can see, there is no difference between the shape of
the emission curves of the conjugates and daunomycin.
However, the fluorescence intensity of the conjugates decreased
markedly as compared to free daunomycin. In this respect, there
is also significant between the two conjugates cAD-EAK and
cAD-SAK, i.e., the fluorescence intensity of cAD-EAK conju-
gate is lower than that of cAD-SAK conjugate.
There are two possible reasons for this decrease in fluorescent
intensity of daunomycin in its conjugated form. Alteration of
electronic structure may involve the excitable electrons of
daunomycin and results a consequent change in its fluorescence
lifetime. This is not very probable since the spectral distributions
of the light emitted by the free and conjugated are the same. The
other possibility is that the daunomycin fluorescence is
quenched by the peptide part of the conjugate. This concept
can be supported also by the strong influence of peptide structure
on the fluorescent intensity and not on the fluorescence spec-
trum. However, further experiments-lifetime measurements and
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other possibility.
In addition, the pH dependence of the emission spectra of the
sample was recorded. The spectrum of daunomycin was pH
dependent, decreasing the pH the fluorescence maximum of the
spectra slightly increased. But no essential changes in the
spectra of conjugates were observed as a function of pH.
4. Discussion
The aim of this study was to analyse the influence of the
carrier structure, predominantly charge properties, on in vitro
antitumor effect and on the cellular uptake of branched chain
polypeptide conjugates with Dau. Previously, we have demon-
strated that amphoteric cAD-EAK conjugate has pronounced in
vivo antitumor effect on L1210 leukemia bearing mice [22].
However, similar conjugate with polycationic carrier did not
inhibit the tumor growth [12]. In order to understand the
difference observed, we have dissected biodistribution related
events (blood clearance, tissue distribution) from those
occurring at cellular level. It should be noted that acid labile
cis-aconityl spacer [12] was used in both conjugates to connect
daunomycin and polypeptide carrier.
First, we have analysed the effects of carrier polypeptide on
the liberation of daunomycin under conditions mimicking the
pH of biological fluids. In this study, we have used buffer with
neutral (pH 7.4) or acidic (pH 3.0–5.0) characteristics
modelling circumstances in human serum and lysosome
compartment, respectively. Our data show that the rate of the
drug release was time-, pH- and temperature-dependent in the
case of both conjugates. Lowering the pH resulted in higher
drug liberation. The rate of the drug release was higher at 37 °C
than at 25 °C at every pH. While only about 50% of the
conjugated drug was liberated from both conjugates at 25 °C at
pH 3, almost the total amount of carrier- bound daunomycin
was released at 37 °C. It should be noted that in the secondary
lysosome the pH is between 5.0 [27] and 4.0 [28]. At pH 4.0, we
found that 70% of the covalently attached daunomycin was
released at 37 °C from these conjugates. From this, one can
conclude that no complete liberation could occur within the cell
even in acid labile spacer in the construct. Similar findings were
reported by Etrych et al. in a comparative study, the authors
studied HPMA-doxorubicin conjugates with different linkages
(cis-aconityl, hydrazone or catepsin sensitive GFLG) and found
100% drug release from conjugates containing the hydrazone
bond [29]. It is important to note that elevation of temperature
from 25 °C to 37 °C resulted in a dramatic increase in the release
of the drug. This finding – for the first in the literature – sug-
gests the marked role of temperature on the drug liberation in
conjugates with cis-aconityl linkage. Based on our data, we
could conclude that the chemical structure and charge
characteristics of polypeptide carrier (amphoteric EAK or
polycationic SAK) had negligible effect on daunomycin
liberation.
In order to study the interaction between of cAD-conjugates
and simple, artificial phospholipid bilayer composed of neutral
and saturated DPPC, fluorescence anisotropy experiments werecarried out. Interaction of daunomycin with model membranes
has been already studied by several authors [30]. It has been
found that Dau perturbs the lipid phase transition associated
with thermodynamic parameters: it decreases the enthalpy
change, lowers the transition temperature. The main phase
transition of saturated phospholipid bilayer was significantly
broadened in the presence of daunomycin indicating a reduced
co-operative behavior of the phospholipid molecules [31]. It has
been proposed that daunomycin is preferentially, but not
exclusively could be localized at membrane ‘surface’ domains.
A smaller population of the membrane-associated Dau can
diffuse into deeper hydrophobic regions [32]. The analysis of
data derived from DPPC studies in the presence of cAD-EAK
showed higher values as compared to the references. The Tc
values derived from the respective curves indicate that cAD-
EAK increases the microviscosity of the DPPC bilayer.
Similarly, the anisotropy profiles of both probes in the presence
of cAD-SAK conjugate suggest almost no interaction with pure
DPPC. Our data show that the conjugates are able to interact
with model membranes applied, but this effect is proved to be
dependent on the carrier part of the constructs. It is attractive to
speculate that the cellular uptake of conjugates could be related
to the level of membrane destabilisation induced by cAD-
conjugates with amphoteric or polycationic polypeptide.
For comparing the antitumor effect of amphoteric cAD-EAK
and polycationic cAD-SAK, four different cell lines (L1210
murine leukemia, c26 murine colon carcinoma, HL-60 human
leukemia and MDA-MB 435 P human leukemia) were used in
our experiments. Data suggest that both conjugates were more
effective against leukemia cells (murine and human leukemia
cells) than on adherent cells of different origin (murine colon
carcinoma or human breast carcinoma). The most pronounced
cytotoxic effect of both cAD-conjugates as well as of free
daunomycin was detected on HL-60 human leukemia cells. It
should be noted that in the clinical application, daunomycin
alone or in combination therapy has been usually used for the
treatment of leukemia [33]. On the basis of the carrier charge,
significant difference of the antitumor effect of the conjugates
containing amphoteric or polycationic polypeptide was found
only against the c26 murine colon carcinoma cells. In contrast,
the cAD-EAK and cAD-SAK conjugates had almost identical
antitumor effect on human breast carcinoma, murine and human
leukemia cell lines, so the cytotoxic effect was independent of
the structural (e.g., charge) properties of the carrier polypeptide.
However, on c26 cells we observed pronounced carrier effect.
Taken together, our data suggest that the antitumor effect of
conjugates on three cell lines was almost independent from
the polypeptide carrier used, but showed marked cell line
dependency.
Considering that both conjugates were highly cytotoxic on
HL-60 cells, we have studied their uptake. These preliminary
experiments to compare the intracellular distribution of the Dau
with that of the conjugates showed significant differences. The
free daunomycin localized both in the cytosol and in the
nucleus, but both of the conjugates was visible only in the
cytoplasm of the HL-60 cells even after 24 h incubation under
the circumstances studied. This observation is in opposite with
288 J. Reményi et al. / Biochimica et Biophysica Acta 1758 (2006) 280–289the speculations in the literature [34], but is in good agreement
with experimental data of Hovorka et al., Kratz et al. and
Rodrigues et al. Using laser scanning confocal microscopy
Kratz et al. showed that free doxorubicin accumulated in the cell
nucleus, whereas its transferrin conjugate localized primarily in
the cytoplasm of MDA-MB-468 breast cancer and of LXFL 529
cells after a 24 h incubation [35]. Similar findings were reported
by Rodrigues et al. by fluorescence microscopy. The authors
demonstrated the presence of PEG-doxorubicin conjugate also
predominantly in the cytoplasm of LXFL 529 lung cancer cells
and the free drug appeared in the nucleus [36]. Hovorka et al.
compared the accumulation of N-(2-hydroxypropyl)methacry-
lamide-(pHPMA)-GFLG-bound doxorubicin and of free drug
[37]. They were unable to detect doxorubicin-related signal in
the nucleus after 72 h incubation in conjugate treated cells,
while the free doxorubicin accumulated in a relatively high
quantity after 90 min incubation.
Interestingly, Omelyanenko et al. observed doxorubicin
related fluorescence in fixed HepG2 and OVCAR-3 cells in the
nucleus after the uptake of the HPMA conjugate [38]. The
authors assumed that doxorubicin released from the conjugate
was responsible for the red colour in the confocal microscopy
images. These data together with our own findings suggest that
the mechanism of action of the conjugate is probably different
from that of the free drug. To verify this proposition and to
understand better the mechanism of action (e.g., the route of
uptake) of cAD-EAK or cAD-SAK conjugates further experi-
ments are in progress.
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